IFN-γ-Induced TNFR2 Expression Is Required for TNF-Dependent Intestinal Epithelial Barrier Dysfunction

Gastroenterology

Volumn 131, Issue 4, 2006, Pages 1153-1163

  Wang, Fengjun ^a,b   Schwarz, Brad T ^b   Graham, W Vallen ^b   Wang, Yingmin ^b   Su, Liping ^b   Clayburgh, Daniel R ^b   Abraham, Clara ^b   Turner, Jerrold R ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD45 ANTIGEN; GAMMA INTERFERON; MYOSIN II; TUMOR NECROSIS FACTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; CHEMICAL ANALYSIS; COLITIS; CONTROLLED STUDY; ENTEROPATHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM; MONOLAYER CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; TIGHT JUNCTION;

EID: 33749466490     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.08.022     Document Type: Article

References (56)

1. Suenaert P., Bulteel V., Lemmens L., Noman M., Geypens B., Van Assche G., Geboes K., Ceuppens J.L., and Rutgeerts P. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97 (2002) 2000-2004
2. Zolotarevsky Y., Hecht G., Koutsouris A., Gonzalez D.E., Quan C., Tom J., Mrsny R.J., and Turner J.R. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 123 (2002) 163-172
3. Taylor C.T., Dzus A.L., and Colgan S.P. Autocrine regulation of epithelial permeability by hypoxia: role for polarized release of tumor necrosis factor α. Gastroenterology 114 (1998) 657-668
4. Clayburgh D.R., Barrett T.A., Tang Y., Meddings J.B., Van Eldik L.J., Watterson D.M., Clarke L.L., Mrsny R.J., and Turner J.R. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest 115 (2005) 2702-2715
5. Wang F., Graham W.V., Wang Y., Witkowski E.D., Schwarz B.T., and Turner J.R. Interferon-γ and tumor necrosis factor-α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 166 (2005) 409-419
6. Blair S.A., Kane S.V., Clayburgh D.R., and Turner J.R. Epithelial myosin light chain kinase expression and activity are up-regulated in inflammatory bowel disease. Lab Invest 86 (2006) 191-201
7. Yacyshyn B.R., and Meddings J.B. CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology 108 (1995) 132-137
8. Shen C., Van Assche G., Rutgeerts P., and Ceuppens J.L. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 12 (2006) 22-28
9. Agnholt J., and Kaltoft K. Infliximab down-regulates interferon-γ production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 15 (2001) 212-222
10. Dimakou K., Papaioannides D., Latsi P., Katsimboula S., Korantzopoulos P., and Orphanidou D. Disseminated tuberculosis complicating anti-TNF-α treatment. Int J Clin Pract 58 (2004) 1052-1055
11. Molenaar E.T., Bultink I.E., Dijkmans B.A., and Lems W.F. Development of fatal tuberculosis in a patient with rheumatoid arthritis after three years of treatment with infliximab: comment on the article by Wolfe et al. Arthritis Rheum 52 (2005) 1334-1336
12. Jarnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlen P., Granno C., Vilien M., Strom M., Danielsson A., Verbaan H., Hellstrom P.M., Magnuson A., and Curman B. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
13. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M., Pritchard M.L., and Sandborn W.J. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 (2006) 621-630
14. Turner J.R., Rill B.K., Carlson S.L., Carnes D., Kerner R., Mrsny R.J., and Madara J.L. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol 273 (1997) C1378-C1385
15. Peterson M.D., and Mooseker M.S. Characterization of the enterocyte-like brush border cytoskeleton of the C2BBe clones of the human intestinal cell line, Caco-2. J Cell Sci 102 (1992) 581-600
16. +-glucose cotransport. Proc Natl Acad Sci U S A 101 (2004) 9485-9490
17. +-glucose cotransport. Am J Physiol Gastrointest Liver Physiol 281 (2001) G1487-G1493
18. Ma T.Y., Boivin M.A., Ye D., Pedram A., and Said H.M. Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 288 (2005) G422-G430
19. Powrie F., Leach M.W., Mauze S., Menon S., Caddle L.B., and Coffman R.L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1 (1994) 553-562
20. Fish S.M., Proujansky R., and Reenstra W.W. Synergistic effects of interferon γ and tumour necrosis factor α on T84 cell function. Gut 45 (1999) 191-198
21. Rothe J., Lesslauer W., Lotscher H., Lang Y., Koebel P., Kontgen F., Althage A., Zinkernagel R., Steinmetz M., and Bluethmann H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364 (1993) 798-802
22. Pfeffer K., Matsuyama T., Kundig T.M., Wakeham A., Kishihara K., Shahinian A., Wiegmann K., Ohashi P.S., Kronke M., and Mak T.W. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73 (1993) 457-467
23. Corredor J., Yan F., Shen C.C., Tong W., John S.K., Wilson G., Whitehead R., and Polk D.B. Tumor necrosis factor regulates intestinal epithelial cell migration by receptor-dependent mechanisms. Am J Physiol Cell Physiol 284 (2003) C953-C961
24. Piguet P.F., Vesin C., Guo J., Donati Y., and Barazzone C. TNF-induced enterocyte apoptosis in mice is mediated by the TNF receptor 1 and does not require p53. Eur J Immunol 28 (1998) 3499-3505
25. Brown G.R., Lee E., and Thiele D.L. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J→C57BL/6J x bm12)F1 mice. J Immunol 168 (2002) 3065-3071
26. Colgan S.P., Parkos C.A., Matthews J.B., D'Andrea L., Awtrey C.S., Lichtman A.H., Delp-Archer C., and Madara J.L. Interferon-γ induces a cell surface phenotype switch on T84 intestinal epithelial cells. Am J Physiol 267 (1994) C402-C410
27. Salomon P., Pizzimenti A., Panja A., Reisman A., and Mayer L. The expression and regulation of class II antigens in normal and inflammatory bowel disease peripheral blood monocytes and intestinal epithelium. Autoimmunity 9 (1991) 141-149
28. Hughes A., Bloch K.J., Bhan A.K., Gillen D., Giovino V.C., and Harmatz P.R. Expression of MHC class II (Ia) antigen by the neonatal enterocyte: the effect of treatment with interferon-γ. Immunology 72 (1991) 491-496
29. Rocha F., Musch M.W., Lishanskiy L., Bookstein C., Sugi K., Xie Y., and Chang E.B. IFN-γ down-regulates expression of Na(+)/H(+) exchangers NHE2 and NHE3 in rat intestine and human Caco-2/bbe cells. Am J Physiol Cell Physiol 280 (2001) C1224-C1232
30. Youakim A., and Ahdieh M. Interferon-γ decreases barrier function in T84 cells by reducing ZO- 1 levels and disrupting apical actin. Am J Physiol 276 (1999) G1279-G1288
31. Zeissig S., Bojarski C., Buergel N., Mankertz J., Zeitz M., Fromm M., and Schulzke J.D. Down-regulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor α antibody treatment. Gut 53 (2004) 1295-1302
32. Gitter A.H., Bendfeldt K., Schulzke J.D., and Fromm M. Leaks in the epithelial barrier caused by spontaneous and TNF-α-induced single-cell apoptosis. FASEB J 14 (2000) 1749-1753
33. Bruewer M., Luegering A., Kucharzik T., Parkos C.A., Madara J.L., Hopkins A.M., and Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171 (2003) 6164-6172
34. Shen L., Black E.D., Witkowski E.D., Lencer W.I., Guerriero V., Schneeberger E.E., and Turner J.R. Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. J Cell Sci 119 (2006) 2095-2106
35. Clayburgh D.R., Shen L., and Turner J.R. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 84 (2004) 282-291
36. Hill G.R., and Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 (2000) 2754-2759
37. Hollander D. Is Crohn's a tight junction disease?. Gut 21 (1989) 315-319
38. Hollander D. Permeability in Crohn's disease: altered barrier functions in healthy relatives?. Gastroenterology 104 (1993) 1848-1851
39. Meddings J.B., Sutherland L.R., and May G.R. Intestinal permeability in patients with Crohn's disease. Gut 35 (1994) 1675-1676
40. Suenaert P., Bulteel V., Vermeire S., Noman M., Van Assche G., and Rutgeerts P. Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis 11 (2005) 667-673
41. Arnott I.D., Kingstone K., and Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 35 (2000) 1163-1169
42. Wyatt J., Vogelsang H., Hubl W., Waldhoer T., and Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 341 (1993) 1437-1439
43. Ozaki H., Ishii K., Horiuchi H., Arai H., Kawamoto T., Okawa K., Iwamatsu A., and Kita T. Cutting edge: combined treatment of TNF-α and IFN-γ causes redistribution of junctional adhesion molecule in human endothelial cells. J Immunol 163 (1999) 553-557
44. Prasad S., Mingrino R., Kaukinen K., Hayes K.L., Powell R.M., MacDonald T.T., and Collins J.E. Inflammatory processes have differential effects on Claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 85 (2005) 1139-1162
45. Van Itallie C., Rahner C., and Anderson J.M. Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability. J Clin Invest 107 (2001) 1319-1327
46. Simon D.B., Lu Y., Choate K.A., Velazquez H., Al-Sabban E., Praga M., Casari G., Bettinelli A., Colussi G., Rodriguez-Soriano J., McCredie D., Milford D., Sanjad S., and Lifton R.P. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 285 (1999) 103-106
47. Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., Mankertz J., Gitter A.H., Burgel N., Fromm M., Zeitz M., Fuss I., Strober W., and Schulzke J.D. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129 (2005) 550-564
48. Mizoguchi E., Mizoguchi A., Takedatsu H., Cario E., de Jong Y.P., Ooi C.J., Xavier R.J., Terhorst C., Podolsky D.K., and Bhan A.K. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology 122 (2002) 134-144
49. Sashio H., Tamura K., Ito R., Yamamoto Y., Bamba H., Kosaka T., Fukui S., Sawada K., Fukuda Y., Satomi M., Shimoyama T., and Furuyama J. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively. Immunogenetics 53 (2002) 1020-1027
50. +-ATPase. J Clin Invest 110 (2002) 1739-1747
51. Alexopoulou L., Pasparakis M., and Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 27 (1997) 2588-2592
52. Pinckard J.K., Sheehan K.C., and Schreiber R.D. Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells. J Biol Chem 272 (1997) 10784-10789
53. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., and Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10 (1999) 387-398
54. Douni E., and Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin α, or the p55TNF-R. J Exp Med 188 (1998) 1343-1352
55. Kollias G., and Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 13 (2002) 315-321
56. van der Klooster J.M., Bosman R.J., Oudemans-van Straaten H.M., van der Spoel J.I., Wester J.P., and Zandstra D.F. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 29 (2003) 2327-2329